HC Wainwright set a $30.00 price target on Omeros (NASDAQ:OMER) in a research note issued to investors on Thursday, January 4th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Cowen lowered Omeros from an outperform rating to a market perform rating in a research report on Thursday, November 2nd. Zacks Investment Research raised Omeros from a sell rating to a hold rating in a research report on Wednesday, November 15th. Maxim Group set a $24.00 target price on Omeros and gave the company a buy rating in a research report on Friday, October 20th. Finally, Wedbush reaffirmed an outperform rating and set a $47.00 target price on shares of Omeros in a research report on Tuesday, November 28th. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Omeros presently has a consensus rating of Buy and an average price target of $34.14.

Shares of Omeros (OMER) traded down $0.11 during trading hours on Thursday, hitting $16.77. The stock had a trading volume of 202,642 shares, compared to its average volume of 707,200. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74. Omeros has a one year low of $9.07 and a one year high of $27.09. The firm has a market capitalization of $810.30, a price-to-earnings ratio of -13.00 and a beta of 3.56.

Omeros (NASDAQ:OMER) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. The firm had revenue of $21.66 million for the quarter, compared to analyst estimates of $17.82 million. Omeros’s revenue for the quarter was up 91.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.34) earnings per share. research analysts anticipate that Omeros will post -0.98 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in OMER. First Interstate Bank purchased a new position in shares of Omeros during the 3rd quarter valued at about $108,000. Legal & General Group Plc raised its holdings in shares of Omeros by 7.8% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 751 shares in the last quarter. Hanseatic Management Services Inc. raised its holdings in shares of Omeros by 10,919.6% during the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 10,592 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Omeros during the 3rd quarter valued at about $256,000. Finally, SG Americas Securities LLC raised its holdings in shares of Omeros by 138.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 7,067 shares in the last quarter. 50.26% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Omeros (NASDAQ:OMER) Given a $30.00 Price Target at HC Wainwright” was first posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.mareainformativa.com/2018/01/30/hc-wainwright-analysts-give-omeros-omer-a-30-00-price-target-updated-updated-updated.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.